Serology Testing, also known as antibody testing, plays a crucial role in vaccine development, monitoring vaccine effectiveness, and assessing population immunity. This diagnostic technique involves detecting and measuring the levels of antibodies in a person's blood, which can indicate past or current infection with a specific pathogen or exposure to a vaccine. In the context of vaccines, serology testing is used to evaluate the immune response elicited by vaccination. After receiving a vaccine, the body typically produces antibodies specific to the antigens contained in the vaccine. Serology testing allows healthcare providers and researchers to assess whether an individual has developed a sufficient antibody response to the vaccine and determine their level of immunity against the target disease.
Serology testing is particularly useful for monitoring the effectiveness of vaccines over time and identifying populations that may require booster doses to maintain immunity. For example, serological studies have been used to assess the duration of immunity following vaccination against diseases such as measles, mumps, rubella, and hepatitis B. In addition to evaluating vaccine responses, serology testing can also be used to assess population immunity and monitor disease outbreaks. By testing samples from a representative sample of the population, public health authorities can estimate the proportion of individuals who have been infected with a particular pathogen or vaccinated against it, providing valuable insights into the overall level of immunity within the community.
Serology testing has played a crucial role in the global response to the COVID-19 pandemic. Antibody tests have been developed to detect antibodies specific to SARS-CoV-2, the virus that causes COVID-19, allowing healthcare providers to identify individuals who have been previously infected with the virus and potentially developed immunity. Serological surveys have also been conducted to assess the prevalence of COVID-19 infection in different populations and inform public health decision-making.
Title : Personalized and Precision Medicine (PPM) via biodesign-driven translational applications and upgraded business modeling to secure the human biosafety: The next-step vaccinomics of the future
Sergey V Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : The promise of nanotechnology in Personalized & Precision Medicine: Nano-driven precision vaccinomics of the future
Sergey V Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Recombinant BCG vaccine as a potent anti tuberculosis vaccine candidate
Sajal Dey, BRIC-Centre for DNA Fingerprinting and Diagnostics, India
Title : Emerging nanovaccine strategies for enhanced immune targeting and vaccine performance
Aysel Sadayli, V.Y. Axundov Scientific-Research Institute of Medical Prophylaxis, Azerbaijan
Title : Advancing vaccine availability and equity in low-resource settings: Evidence from Awendo Sub-County, Kenya
Millicent Ochieng, Clinton Health Access Initiative, Kenya
Title : Reaching zero-dose children through adaptive immunization strategies in security-compromised areas of Zamfara State, Nigeria
Attahir Abubakar, Ahmadu Bello University, Nigeria
Title : From local pilots to national policy: Key issues and challenges in implementing nationwide HPV vaccination in China
Shenglan Tang, Duke Global Health Institute, United States